Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity

Journal of Clinical Pharmacology

Volumn 45, Issue 10, 2005, Pages 1187-1197

  Kharasch, Evan D ^a   Walker, Alysa ^a   Hoffer, Christine ^a   Sheffels, Pamela ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alfentanil; CYP3A; Drug metabolism; Midazolam; Miosis

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A; FLUCONAZOLE; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MIOSIS; NAUSEA; NORMAL HUMAN; OXYGEN SATURATION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ALFENTANIL; ANALGESICS, OPIOID; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDAZOLAM; MIOSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 25444518701     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280077     Document Type: Article

References (52)

1. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171-184.
2. Zaigler M, Tantcheva-Poor I, Fuhr U. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther. 2000;38:1-9.
3. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
4. Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther. 2001;70:103-114.
5. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-832.
6. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Advan Drug Delivery Rev. 1997;27:161-170.
7. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2000;32:339-361.
8. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
9. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294.
10. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30:883-891.
11. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003;3:3-5.
12. Harris R, Jang G, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071-1088.
13. Gibbs MA, Hosea NA, Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet. 2003;42: 969-984.
14. Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet. 2001;40:151-158.
15. Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther. 2001;70:305-310.
16. McCrea J, Prueksaritanont T, Gertz BJ, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999;39:1212-1220.
17. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther. 2002; 72:524-535.
18. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome CYP3A and CYP2B6 in the metabolism, disposition and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250-269.
19. Klotz U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther. 1982;32:107-112.
20. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther. 2003;73: 153-158.
21. Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH. Influence of food on midazolam absorption. J Clin Pharmacol. 1986;26:55-59.
22. Strömberg C, Vanakoski J, Olkkola KT, Lindqvist A, Seppälä T, Laitinen LA. Exercise alters the pharmacokinetics of midazolam. Clin Pharmacol Ther. 1992;51:527-532.
23. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51:715-728.
24. Yun C-H, Wood M, Wood AJJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. An explanation of the variable elimination clearance. Anesthesiology. 1992;77:467-474.
25. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos. 1995;23:490-496.
26. Klees TM, Sheffels P, Thummel KE, Kharasch ED. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005; 102:550-556.
27. Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg. 1986;65: 999-1003.
28. Chauvin M, Lebrault C, Levron JC, Duvaldestin P. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg. 1987;66: 53-56.
29. Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, Duvaldestin P. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology. 1985;62:480-484.
30. Meuldermans W, Van Peer A, Hendrickx J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology. 1988; 69:527-534.
31. Henthorn TK, Krejcie TC, Avram MJ. The relationship between alfentanil distribution kinetics and cardiac output. Clin Pharmacol Ther. 1992;52:190-196.
32. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 1997;87:36-50.
33. Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001;70: 505-517.
34. Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther. 2003; 73:199-208.
35. Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass CYP3A activity: noninvasive assessment using pupillary miosis. Clin Pharmacol Ther. 2004;76:452-466.
36. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology. 1997; 87:26-35.
37. Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KT. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol. 1999;39: 664-669.
38. Kharasch ED, Walker A, Hoffer C, Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol. 2005;45:79-88.
39. Chaobal HN, Kharasch ED. Single point sampling for assessment of constitutive, induced and inhibited CYP3A activity with alfentanil: comparison with midazolam. Clin Pharmacol Ther. In press.
40. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg. 1998;87: 190-194.
41. Gorski JC, Vannaprasaht S, Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275-287.
42. Gries RE, Brooks LJ. Normal oxyhemoglobin saturation during sleep: how low does it go? Chest. 1996;110:1489-1492.
43. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol. 1999; 39:275-280.
44. Raeder JC, Nilsen OG, Hole A. Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia: a study with concomitant thiopentone, flumazenil or placebo administration. Acta Anaesthesiol Scand. 1988;32:467-472.
45. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther. 2001;69:333-339.
46. Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther. 2004;76:341-349.
47. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133-143.
48. Lee J-I, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72:718-728.
49. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66:461-471.
50. van den Nieuwenhuyzen MCO, Engbers FHM, Burm AGL, et al. Computer-controlled infusion of alfentanil for postoperative analgesia: a pharmacokinetic and pharmacodynamic evaluation. Anesthesiology. 1993;79:481-492.
51. Ludtke H, Wilhelm B, Adler M, Schaeffel F, Wilhelm H. Mathematical procedures in data recording and processing of pupillary fatigue waves. Vision Res. 1998;38:2889-2896.
52. O'Neill WD, Oroujeh AM, Keegan AP, Merritt SL. Neurological pupillary noise in narcolepsy. J Sleep Res. 1996;5:265-271.